Asunaprevir-containing regimens for the treatment of hepatitis C virus infection

References

• Global surveillance and control of hepatitis C. Report of a WHO consultation. organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999;6(1):35-47
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infec Dis 2005;5(10):558-67
   PubMed Web of Science ®Google Scholar
• Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61-80
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 –. June 10-12, 2002. Hepatology 2002;36(5 Suppl 1):S3-20
   PubMedGoogle Scholar
• Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997;4(1):9-28
   PubMed Web of Science ®Google Scholar
• Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999;31(Suppl 1):39-42
   Google Scholar
• Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169-77
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59(1):318-27
   PubMed Web of Science ®Google Scholar
• Yu ML, Chuang WL, Chen SC, et al. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001;65(1):58-65
   PubMed Web of Science ®Google Scholar
• Suh DJ, Jeong SH. Current status of hepatitis C virus infection in Korea. Intervirology 2006;49(1-2):70-5
   PubMed Web of Science ®Google Scholar
• Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrison TJ. Diversity of genotypes of hepatitis C virus in southern India. J Gen Virol 1995;76(Pt 3):711-16
   PubMed Web of Science ®Google Scholar
• Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;25(9):2051-67
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56(4):553-9
   PubMed Web of Science ®Google Scholar
• Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47(10):1260-9
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26(1):73-81
   PubMed Web of Science ®Google Scholar
• Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 2008;47(4):1371-83
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone JJr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
   PubMed Web of Science ®Google Scholar
• Torii H, Sueki H, Kumada H, et al. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan. J Dermatol 2013;40(8):587-95
   PubMed Web of Science ®Google Scholar
• Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58(6):1918-29
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a Phase 3 Trial. Gastroenterology 2014;146(7):1669-79
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146(2):430-41
   PubMed Web of Science ®Google Scholar
• Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61(2):219-27
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013;58(4):663-8
   PubMed Web of Science ®Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13(5):401-8
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370(21):1993-2001
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310(8):804-11
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• Michael P, Curry M, Forns X, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Presented at 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1 – 5 November 2013; Washington DC, USA
   Google Scholar
• Cornpropst MT, Denning JM, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; 18 – 22 April 2012; Barcelona, Spain
   Google Scholar
• Herbst DAJr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22(4):527-36
   PubMed Web of Science ®Google Scholar
• Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 2014;7(3):131-40
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368(1):34-44
   PubMed Web of Science ®Google Scholar
• Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20(1):35-40
   PubMedGoogle Scholar
• Coppola N, Pisaturo M, Sagnelli C, et al. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One 2014;9(4):e94542
   PubMed Web of Science ®Google Scholar
• Kim WR, Congley S, Roberts L, et al. Impact of highly effective antiviral therapy on burden of hepatocellular carcinoma in hepatitis C cirrhosis. Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 24 – 28 April 2013; Amsterdam, The Netherlands
   Google Scholar
• Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30
   PubMed Web of Science ®Google Scholar
• Chang CH, Lin JW, Wu LC, et al. National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report. Med Care 2013;51(10):908-13
   PubMed Web of Science ®Google Scholar
• Hsu YC, Ho HJ, Wu MS, et al. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 2013;58(1):150-7
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56(Suppl 1):S88-S100
   PubMed Web of Science ®Google Scholar
• Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013;28(1):38-45
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58(3):583-92
   PubMed Web of Science ®Google Scholar
• Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag 2014;10:493-504
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs 2013;18(4):461-75
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV. Expert Opin Investig Drugs 2014;23(4):561-71
   PubMed Web of Science ®Google Scholar
• Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drugs Des Devel Ther 2013;7:105-15
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12(7):763-73
   PubMed Web of Science ®Google Scholar
• Failla C, Tomei L, De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 1994;68(6):3753-60
   PubMed Web of Science ®Google Scholar
• Schregel V, Jacobi S, Penin F, Tautz N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci USA 2009;106(13):5342-7
   PubMed Web of Science ®Google Scholar
• Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010;21(1):33-40
   PubMed Web of Science ®Google Scholar
• Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005;309(5740):1577-81
   PubMed Web of Science ®Google Scholar
• Liu Z, Yang F, Robotham JM, Tang H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 2009;83(13):6554-65
   PubMed Web of Science ®Google Scholar
• Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012;61(Suppl 1):i25-35
   PubMed Web of Science ®Google Scholar
• Raney KD, Sharma SD, Moustafa IM, Cameron CE. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 2010;285(30):22725-31
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87(2):343-55
   PubMed Web of Science ®Google Scholar
• Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110-13
   PubMed Web of Science ®Google Scholar
• Taylor DR. Evolution of cell culture systems for HCV. Antivir Ther 2013;18(3 Pt B):523-30
   PubMed Web of Science ®Google Scholar
• Hinrichsen H, Benahmou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127(5):1347-55
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, et al. Initial results of a phase 1b, multiple dose study of VX-950, a hepatitis C virus protease inhibitor. Presented at 36th Digestive Disease Week; Chicago, IL, USA; 2005
   Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426(6963):186-9
   PubMed Web of Science ®Google Scholar
• Scola PM, Wang AX, Good AC, et al. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57(5):1708-29
   PubMed Web of Science ®Google Scholar
• Scola PM, Sun LQ, Wang AX, et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57(5):1730-52
   PubMed Web of Science ®Google Scholar
• McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56(10):5387-96
   PubMed Web of Science ®Google Scholar
• Pasquinelli C, McPhee F, Eley T, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012;56(4):1838-44
   PubMed Web of Science ®Google Scholar
• Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin. Available from: http://clinicaltrials.gov/show/NCT01030432
   Google Scholar
• Bronowicki JP, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013;18(7):885-93
   PubMed Web of Science ®Google Scholar
• Study to determine the effectiveness of antiviral combination therapy to treat hepatitis C Virus (HCV) infected patients who have previously failed standard of care. Available from: http://clinicaltrials.gov/show/NCT01012895
   Google Scholar
• Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366(3):216-24
   PubMed Web of Science ®Google Scholar
• Lok A, Gardiner D, Hezode C, et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 9 – 12 November 2012; Boston, MA, USA
   Google Scholar
• Study to determine the effectiveness and safety of a three drug antiviral combination therapy to treat hepatitis C virus (HCV) infected patients not previously treated with currently available medications. Available from: http://clinicaltrials.gov/show/NCT01455090
   Google Scholar
• Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naïve patients with HCV genotype 1 infection. Gastroenterology 2014;146(2):420-9
   PubMed Web of Science ®Google Scholar
• An Anti-viral combination study with japanese hepatitis c infection (HCV) subject. Available from: http://clinicaltrials.gov/show/NCT01051414
   Google Scholar
• Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55(3):742-8
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58(4):655-62
   PubMed Web of Science ®Google Scholar
• A Phase 3 Study in combination with BMS-790052 and BMS-650032 in Japanese hepatitis C virus (HCV) patients. Available from: http://clinicaltrials.gov/show/NCT01497834
   Google Scholar
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59(6):2083-91
   PubMed Web of Science ®Google Scholar
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, intolerants/ineligibles. Naives). Available from: http://clinicaltrials.gov/show/NCT01581203
   Google Scholar
• Manns M, Pol S, Jacobson IM, et al. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: Phase 3 HALLMARK-DUAL study results. Presented at 49th Annual Meeting of the European Association for the Study of the Liver; 9 – 13 April 2014; London, UK
   Google Scholar
• Kao JH, Heo J, Yoffe B, et al. Efficacy and safety of daclatasvir in combination with asunaprevir in cirrhotic and non-cirrhotic patients with HCV genotype 1b: Results of the HALLMARK-DUAL study. Presented at 49th Annual Meeting of the European Association for the Study of the Liver; 9 – 13 April 2014; London, UK
   Google Scholar
• McPhee F, Friborg J, Levine S, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012;56(7):3670-81
   PubMed Web of Science ®Google Scholar
• McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013;58(3):902-11
   PubMed Web of Science ®Google Scholar
• Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013;58(4):646-54
   PubMed Web of Science ®Google Scholar